TABLE 2.

Genes associated with olanzapine pharmacokinetics or pharmacodynamics.

Olanzapine
Pharmacokinetics
Gene	Variant	Association	Associated	Not associated
CYP1A2	*1D	↑[Olanzapine]plasma	(Söderberg and Dahl, 2013; Czerwensky et al., 2015)	(Cabaleiro et al., 2013; Koller et al., 2020)
	*1F	↑[Olanzapine]plasma	(Söderberg and Dahl, 2013; Czerwensky et al., 2015)	(Cabaleiro et al., 2013; Koller et al., 2020)
CYP1A1-CYP1A2	rs2472297	↑[Olanzapine]plasma	Söderberg and Dahl, (2013)
CYP2D6	UM	No effect		(Nozawa et al., 2008; Söderberg and Dahl, 2013; Koller et al., 2020
				Zubiaur et al. (2021)
	PM	↑Insulin levels	Koller et al. (2021)
CYP3A5	*3/*3	↓AUC	Cabaleiro et al. (2013)	Zubiaur et al. (2021)
CYP2C9	PM	↑Adverse drug reactions	(Cabaleiro et al., 2013; Zubiaur et al., 2021)
ABCB1	rs1045642	↑AUC	(Skogh et al., 2011; Saiz-Rodríguez et al., 2018)
	rs2032582	↑AUC	(Skogh et al., 2011; Saiz-Rodríguez et al., 2018)
	rs1128503	↑[Olanzapine]plasma	Skogh et al. (2011)
	rs3842	↑Olanzapine exposure	Zubiaur et al. (2021)
	Others	Variation T1/2	Koller et al. (2020)
UGT1A4	*3	↑Glucuronidation	Erickson-Ridout et al. (2011)
UGT2B10	*2	↓Glucuronidation	Erickson-Ridout et al. (2011)
UGT1A1	rs887829	↑Tmax	Koller et al. (2020)
FMO3	rs2266782-rs2266780	↓N-oxidation	Söderberg et al. (2013)
FMO1	*6	↑[Olanzapine]plasma	Söderberg et al. (2013)
Pharmacodynamics
5-HTR2C	rs3813929	↓Weight gain	(Templeman et al., 2005; Sicard et al., 2010)
		↓body Mass index
	rs1414334	↑Risk of metabolic syndrome, ↑Weight gain	(Ma et al., 2014; Koller et al., 2021)
	rs6318	↓Weight gain	(Sicard et al., 2010; Ma et al., 2014)
	rs518147	↓Weight gain	Sicard et al. (2010)
DRD2	rs1800497	↑Prolactin levels	(López-Rodríguez et al., 2011; Brennan, 2014; Zubiaur et al., 2021)	Koller et al. (2021)
		↑Adverse drug reactions
	rs1799732	↑Weight gain	(Lencz et al., 2010; Zubiaur et al., 2021)
		↑Adverse drug reactions
DRD3	rs6280	↑Response to olanzapine, ↑Prolactin levels	(Brennan, 2014; Koller et al., 2021)
APOC3	rs4520	↑Triglyceride levels	Koller et al., (2021)